Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027

Bolt Biotherapeutics, Inc.

Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.
R&D expenses $28.5M in FY2025, down from $57.5M in FY2024; G&A $13.8M vs $18.5M, driven by restructuring.
Loss from operations $36.1M for FY2025 vs $73.0M in FY2024.
Cash, cash equivalents and marketable securities $31.8M as of Dec 31, 2025; expected to fund milestones into 2027.
Initial clinical data for BDC-4182 Phase 1 study (CLDN18.2) expected in Q3 2026; step-up dosing added to protocol.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $2.5 million
Result: reported results

Exact text from the filing

Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $7.7 million.

Period: the full year ended December 31, 2025
Revenue: $7.7 million
Result: reported results

Exact text from the filing

Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-104102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.